Lynch, K., Chapman, R., Keshav, S., Montano-Loza, A., Mason, A., Kremer, A., . . . Levy, C. (2019). Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Elsevier.
Cita Chicago (17th ed.)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
Cita MLA (9th ed.)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
Atenció: Aquestes cites poden no estar 100% correctes.